Lorigerlimab
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) . Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) [1][2][3].
Product Specifications
CAS Number
2416595-46-3
Product Name Alternative
MGD019
UNSPSC
12352203
Target
CTLA-4; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lorigerlimab.html
Purity
97.5
Solubility
10 mM in DMSO
Smiles
[Lorigerlimab]
Molecular Weight
(166.4 kDa)
References & Citations
[1]Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1xCTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) : A phase 1 expansion (exp) cohort. Journal of Clinical Oncology 2023 41:6_suppl, 155-155. |[2]Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1 (9) :100163. |[3]Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol. 2021 Jun 10;11:670726.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
M2423-20A-01 5 µg
Matrix Metalloproteinase 7, Recombinant Human (MMP-7, Matrilysin, Pump1, Uterine Metalloproteinase) discontinued. see M2423-20
Sign In for Pricing
View Details M2423-20A-02 20 µg
Matrix Metalloproteinase 7, Recombinant Human (MMP-7, Matrilysin, Pump1, Uterine Metalloproteinase) discontinued. see M2423-20
Sign In for Pricing
View Details 
